Supplemental data from Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers

MLA

Stephen S. Hecht, et al. Supplemental Data from Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1940-6207.22534253.

APA

Stephen S. Hecht, Dorothy Hatsukami, Mimi C. Yu, Heather H. Nelson, Mindy S. Kurzer, Chap Le, Pramod Upadhyaya, Jennifer Adams-Haduch, Lori Strayer, Joni Jensen, Sharon Allen, Renwei Wang, Sharon E. Murphy, Irina Stepanov, & Jian-Min Yuan. (2023). Supplemental data from Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers. https://doi.org/10.1158/1940-6207.22534253

Chicago

Stephen S. Hecht, Dorothy Hatsukami, Mimi C. Yu, Heather H. Nelson, Mindy S. Kurzer, Chap Le, Pramod Upadhyaya, et al. 2023. “Supplemental Data from Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers,” April. doi:10.1158/1940-6207.22534253.